Modality
Small Molecule
MOA
Menini
Target
CD20
Pathway
Notch
Gastric CaHCCAsthma
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
Jan 2018
→ Feb 2027
Phase 1Current
NCT06737966
1,627 pts·HCC
2018-01→2027-02·Not yet recruiting
1,627 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-2411mo awayInterim· HCC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Not yet…
Catalysts
Interim
2027-02-24 · 11mo away
HCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06737966 | Phase 1 | HCC | Not yet recr... | 1627 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| AKR-4818 | Akero | Approved | CD20 |